| abstract |
Provided is a novel assessment method for stroke and cerebral infarction (in particular, asymptomatic cerebral infarction) without any burden on a subject to be tested. It is newly found that the content of 3-HPMA, which is a metabolite of acrolein, in a urine specimen decreases in a stroke patient as compared to a healthy subject without history of stroke, irrespective of smoking habits and gender, which is quite different from the result expected from a conventional finding. Thus, an assessment method for stroke and/or cerebral infarction, including using 3-HPMA in a urine specimen as an indicator, is completed. |